Cigna Medical Coverage Policies – Radiology
Cardiac Imaging
Effective August 1, 2019

Instructions for use
The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:

1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

These guidelines include procedures eviCore does not review for Cigna. Please refer to the Cigna CPT code list for the current list of high-tech imaging procedures that eviCore reviews for Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.
<table>
<thead>
<tr>
<th>Cardiac Imaging Guidelines</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations For Cardiac Imaging Guidelines</td>
<td>3</td>
</tr>
<tr>
<td>Glossary</td>
<td>4</td>
</tr>
<tr>
<td>CD-1: General Guidelines</td>
<td>5</td>
</tr>
<tr>
<td>CD-2: Echocardiography (ECHO)</td>
<td>15</td>
</tr>
<tr>
<td>CD-3: Nuclear Cardiac Imaging</td>
<td>27</td>
</tr>
<tr>
<td>CD-4: Cardiac CT, Coronary CTA, and CT for Coronary Calcium (CAC)</td>
<td>33</td>
</tr>
<tr>
<td>CD-5: Cardiac MRI</td>
<td>41</td>
</tr>
<tr>
<td>CD-6: Cardiac PET</td>
<td>46</td>
</tr>
<tr>
<td>CD-7: Diagnostic Heart Catheterization</td>
<td>49</td>
</tr>
<tr>
<td>CD-8: Pulmonary Artery and Vein Imaging</td>
<td>56</td>
</tr>
<tr>
<td>CD-9: Congestive Heart Failure</td>
<td>59</td>
</tr>
<tr>
<td>CD-10: Cardiac Trauma</td>
<td>62</td>
</tr>
<tr>
<td>CD-11: Section left intentionally blank</td>
<td>64</td>
</tr>
<tr>
<td>CD-12: Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)</td>
<td>65</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>ACC</td>
<td>American College of Cardiology</td>
</tr>
<tr>
<td>ACS</td>
<td>acute coronary syndrome</td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>ASCOT</td>
<td>Anglo-Scandinavian Cardiac Outcomes Trial</td>
</tr>
<tr>
<td>ASD</td>
<td>atrial septal defect</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>CABG</td>
<td>coronary artery bypass grafting</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CCTA</td>
<td>coronary computed tomography angiography</td>
</tr>
<tr>
<td>CTA</td>
<td>computed tomography angiography</td>
</tr>
<tr>
<td>EBCT</td>
<td>electron beam computed tomography</td>
</tr>
<tr>
<td>ECP</td>
<td>external counterpulsation (also known as EECP)</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ECP</td>
<td>external counterpulsation</td>
</tr>
<tr>
<td>ETT</td>
<td>exercise treadmill stress test</td>
</tr>
<tr>
<td>FDG</td>
<td>Fluorodeoxyglucose, a radiopharmaceutical used to measure myocardial metabolism</td>
</tr>
<tr>
<td>HCM</td>
<td>hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>LAD</td>
<td>left anterior descending coronary artery</td>
</tr>
<tr>
<td>LDL-C</td>
<td>low density lipoprotein cholesterol</td>
</tr>
<tr>
<td>LHC</td>
<td>left heart catheterization</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricle</td>
</tr>
<tr>
<td>LVEF</td>
<td>left ventricular ejection fraction</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>MPI</td>
<td>myocardial perfusion imaging (SPECT study, nuclear cardiac study)</td>
</tr>
<tr>
<td>MRA</td>
<td>magnetic resonance angiography</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>mSv</td>
<td>millisievert (a unit of radiation exposure) equal to an effective dose of a joule of energy per kilogram of recipient mass</td>
</tr>
<tr>
<td>MUGA</td>
<td>multi gated acquisition scan of the cardiac blood pool</td>
</tr>
<tr>
<td>PCI</td>
<td>percutaneous coronary intervention (includes percutaneous coronary angioplasty (PTCA) and coronary artery stenting)</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PTCA</td>
<td>percutaneous coronary angioplasty</td>
</tr>
<tr>
<td>RHC</td>
<td>right heart catheterization</td>
</tr>
<tr>
<td>SPECT</td>
<td>single photon emission computed tomography</td>
</tr>
<tr>
<td>TEE</td>
<td>transesophageal echocardiogram</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient Ischemic Attack</td>
</tr>
<tr>
<td>VSD</td>
<td>ventricular septal defect</td>
</tr>
</tbody>
</table>
## Glossary

**Agatston Score**: a nationally recognized calcium score for the coronary arteries based on Hounsfield units and size (area) of the coronary calcium

**Angina**: principally chest discomfort, exertional (or with emotional stress) and relieved by rest or nitroglycerine

**Anginal variants or equivalents**: a manifestation of myocardial ischemia which is perceived by individuals to be (otherwise unexplained) dyspnea, unusual fatigue, more often seen in women and may be unassociated with chest pain

**ARVD/ARVC – Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy**: a potentially lethal inherited disease with syncope and rhythm disturbances, including sudden death, as presenting manifestations

**BNP**: B-type natriuretic peptide, blood test used to diagnose and track heart failure (n-T-pro-BNP is a variant of this test)

**Brugada Syndrome**: an electrocardiographic pattern that is unique and might be a marker for significant life threatening dysrhythmias

**Double Product (Rate Pressure Product)**: an index of cardiac oxygen consumption, is the systolic blood pressure times heart rate, generally calculated at peak exercise; over 25000 means an adequate stress load was performed

**Fabry’s Disease**: an infiltrative cardiomyopathy, can cause heart failure and arrhythmias

**Hibernating myocardium**: viable but poorly functioning or non-functioning myocardium which likely could benefit from intervention to improve myocardial blood supply

**Optimized Medical Therapy** should include (where tolerated): antiplatelet agents, calcium channel antagonists, partial fatty acid oxidase inhibitors (e.g. ranolazine), statins, short-acting nitrates as needed, long-acting nitrates up to 6 months after an acute coronary syndrome episode, beta blocker drugs (optional), angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blocking (ARB) agents (optional)

**Platypnea**: shortness of breath when upright or seated (the opposite of orthopnea) and can indicate cardiac malformations, shunt or tumor

**Silent ischemia**: cardiac ischemia discovered by testing only and not presenting as a syndrome or symptoms

**Syncope**: loss of consciousness; near-syncope is not syncope

**Takotsubo cardiomyopathy**: apical dyskinesis oftentimes associated with extreme stress and usually thought to be reversible

**Troponin**: a marker for ischemic injury, primarily cardiac
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-1.1</td>
<td>General Issues – Cardiac</td>
<td>6</td>
</tr>
<tr>
<td>CD-1.2</td>
<td>Stress Testing without Imaging – Procedures</td>
<td>8</td>
</tr>
<tr>
<td>CD-1.3</td>
<td>Stress Testing with Imaging – Procedures</td>
<td>8</td>
</tr>
<tr>
<td>CD-1.4</td>
<td>Stress Testing with Imaging – Indications</td>
<td>8</td>
</tr>
<tr>
<td>CD-1.5</td>
<td>Stress Testing with Imaging – Preoperative</td>
<td>10</td>
</tr>
<tr>
<td>CD-1.6</td>
<td>Transplant Individuals</td>
<td>11</td>
</tr>
<tr>
<td>CD-1.7</td>
<td>Non-imaging Heart Function and Cardiac Shunt Imaging</td>
<td>12</td>
</tr>
<tr>
<td>CD-1.8</td>
<td>Section left intentionally blank</td>
<td>12</td>
</tr>
</tbody>
</table>
Practice Estimate of Effective Radiation Dose chart for Selected Imaging Studies

<table>
<thead>
<tr>
<th>IMAGING STUDY</th>
<th>Estimate of Effective Radiation Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sestamibi myocardial perfusion study (MPI)</td>
<td>9-12 mSv</td>
</tr>
<tr>
<td>PET myocardial perfusion study:</td>
<td>3 mSV</td>
</tr>
<tr>
<td>Rubidium-82</td>
<td>2 mSV</td>
</tr>
<tr>
<td>NH3</td>
<td></td>
</tr>
<tr>
<td>Thallium myocardial perfusion study (MPI)</td>
<td>22-31 mSv</td>
</tr>
<tr>
<td>Diagnostic conventional coronary angiogram (cath)</td>
<td>5-10 mSv</td>
</tr>
<tr>
<td>Computed tomography coronary angiography (CTCA) (with prospective gating)</td>
<td>5-15 mSv</td>
</tr>
<tr>
<td>CT of Abdomen and pelvis</td>
<td>8-14 mSv</td>
</tr>
<tr>
<td>Chest x-ray</td>
<td>&lt;0.1 mSv</td>
</tr>
</tbody>
</table>

CD-1.1: General Issues – Cardiac

- Cardiac imaging is not indicated if the results will not affect individual management decisions. If a decision to perform cardiac catheterization or other angiography has already been made, there is often no need for imaging stress testing.
- A current clinical evaluation (within 60 days) is required prior to considering advanced imaging, which includes:
  - Relevant history and physical examination and appropriate laboratory studies and non-advanced imaging modalities, such as recent ECG (within 60 days), chest x-ray or ECHO/ultrasound, after symptoms started or worsened.
    - Effort should be made to obtain copies of reported “abnormal” ECG studies in order to determine whether the ECG is uninterpretable for ischemia on ETT.
    - Most recent previous stress testing and its findings should be obtained.
    - Other meaningful contact (telephone call, electronic mail or messaging) by an established individual can substitute for a face-to-face clinical evaluation.
  - Vital signs, height and weight or BMI or description of general habitus is needed.
  - Advanced imaging should answer a clinical question which will affect management of the individual’s clinical condition.
  - Assessment of coronary artery disease can be determined by the following:
    - Typical angina (definite):
      - Substernal chest discomfort (generally described as pressure, heaviness, burning, or tightness)
      - Generally brought on by exertion or emotional stress and relieved by rest
      - May radiate to the left arm or jaw
      - When clinical information is received indicating that an individual is experiencing chest pain that is "exertional" or "due to emotional stress", this meets the typical angina definition under the Pre-Test Probability Grid. No further description of the chest pain is required (location within the chest is not required).
The Pre-Test Probability Grid (Table 1) is based on age, gender, and symptoms. All factors must be considered in order to approve for stress testing with imaging using the Pre-Test Probability Grid.

- **Atypical angina (probable):** Chest pain or discomfort (arm or jaw pain) that lacks one of the characteristics of definite or typical angina.
- **Non-anginal chest pain:** Chest pain or discomfort that meets one or none of the typical angina characteristics.
- **Anginal variants or equivalents:** a manifestation of myocardial ischemia which is perceived by individuals to be (otherwise unexplained) dyspnea, nausea, diaphoresis, more often seen in women and may be unassociated with chest pain.

<table>
<thead>
<tr>
<th>Table-1</th>
<th>Pre-Test Probability of CAD by Age, Gender, and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Gender</td>
</tr>
<tr>
<td>39 and younger</td>
<td>Men</td>
</tr>
<tr>
<td></td>
<td>Women</td>
</tr>
<tr>
<td>40 - 49</td>
<td>Men</td>
</tr>
<tr>
<td></td>
<td>Women</td>
</tr>
<tr>
<td>50 - 59</td>
<td>Men</td>
</tr>
<tr>
<td></td>
<td>Women</td>
</tr>
<tr>
<td>60 and over</td>
<td>Men</td>
</tr>
<tr>
<td></td>
<td>Women</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pre-Test Probability</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Greater than 90% pre-test probability</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Between 10% and 90% pre-test probability</td>
</tr>
<tr>
<td>Low</td>
<td>Between 5% and 10% pre-test probability</td>
</tr>
<tr>
<td>Very Low</td>
<td>Less than 5% pre-test probability</td>
</tr>
</tbody>
</table>
CD-1.2: Stress Testing without Imaging – Procedures

The Exercise Treadmill Test (ETT) is without imaging.

- Necessary components of an ETT include:
  - ECG that can be interpreted for ischemia.
  - Individual capable of exercise on a treadmill or similar device (generally at 4 METs or greater; see functional capacity below).

- An abnormal ETT (exercise treadmill test) includes any ONE of the following:
  - ST segment depression (usually described as horizontal or downsloping, greater or equal to 1.0 mm below baseline)
  - Development of chest pain
  - Significant arrhythmia (especially ventricular arrhythmia)
  - Hypotension during exercise

- Functional capacity greater than or equal to 4 METs equates to the following:
  - Can walk four blocks without stopping
  - Can walk up a hill
  - Can climb one flights of stairs without stopping
  - Can perform heavy work around the house

Background and Supporting Information
An observational study found that, compared with the Duke Activity Status Index, subjective assessment by clinicians generally underestimated exercise capacity (See reference 25).

CD-1.3: Stress Testing with Imaging – Procedures

- Imaging Stress Tests include any ONE of the following:
  - Stress Echocardiography See CD-2.6: Stress Echocardiography (Stress Echo) – Coding
  - MPI See CD-3.1: Myocardial Perfusion Imaging (MPI) – Coding
  - Stress perfusion MRI See CD-5.3: Cardiac MRI – Indications for Stress MRI

- Stress testing with imaging can be performed with maximal exercise or chemical stress (adenosine, dipyridamole, dobutamine, or regadenoson) and does not alter the CPT® codes used to report these studies.

CD-1.4: Stress Testing with Imaging – Indications

- Stress echo, MPI or stress MRI if there are new, recurrent, or worsening cardiac symptoms and ANY of the following:
  - High pretest probability (greater than 90% probability of CAD) per Table 1
  - A history of CAD based on:
    - A prior anatomic evaluation of the coronaries OR
    - A history of CABG or PCI
  - Evidence or high suspicion of ventricular tachycardia
  - Age 40 years or greater and known diabetes mellitus
  - Coronary calcium score ≥100
Poorly controlled hypertension defined as systolic BP greater than or equal to 180mmhg, if provider feels strongly that CAD needs evaluation prior to BP being controlled.

ECG is uninterpretable for ischemia due to any one of the following:
- Complete Left Bundle Branch Block (bifascicular block involving right bundle branch and left anterior hemiblock does not render ECG uninterpretable for ischemia)
- Ventricular paced rhythm
- Pre-excitation pattern such as Wolff-Parkinson-White
- Greater or equal to 1.0 mm ST segment depression (NOT nonspecific ST/T wave changes)
- LVH with repolarization abnormalities, also called LVH with strain (NOT without repolarization abnormalities or by voltage criteria)
- T wave inversion in the inferior and/or lateral leads. This includes leads II, AVF, V5 or V6. (T wave inversion isolated in lead III or T wave inversion in lead V1 and V2 are not included).
- Individual on digitalis preparation

Continuing symptoms in an individual who had a normal or submaximal exercise treadmill test and there is suspicion of a false negative result.

Individuals with recent equivocal, borderline, or abnormal stress testing where ischemia remains a concern, regardless of symptoms.

Heart rate less than 50 bpm in individuals, including those on beta blocker, calcium channel blocker, or amiodarone where it is felt that the individual may not achieve an adequate workload for a diagnostic exercise study.

Inadequate ETT:
- Physical inability to achieve target heart rate (85% MPHR or 220-age. Target heart rate is calculated as 85% of the maximum age predicted heart rate (MPHR). MPHR is estimated as 220 minus the individual's age).
- History of false positive exercise treadmill test: a false positive ETT is one that is abnormal however the abnormality does not appear to be due to macrovascular CAD.

Stress echo, MPI or stress MRI, can be considered regardless of symptoms for ANY of the following:

One MPI can be performed within 3 months of an acute coronary syndrome (e.g. ST segment elevation MI [STEMI], unstable angina, non-ST segment elevation MI [NSTEMI]), to evaluate for inducible ischemia if all of the following related to the most recent acute coronary event apply:
- Individual is hemodynamically stable
- No recurrent chest pain symptoms and no signs of heart failure
- No prior coronary angiography or imaging stress test since the current episode of symptoms

Assessing myocardial viability in individuals with significant ischemic ventricular dysfunction (suspected hibernating myocardium) and persistent symptoms or heart failure such that revascularization would be considered.
- MRI, cardiac PET, MPI, or Dobutamine stress echo can be used to assess myocardial viability depending on physician preference.
PET and MPI perfusion studies are usually accompanied by PET metabolic examinations (CPT® 78459). TI-201 MPI perfusion studies may assess viability without accompanying PET metabolism information.

- Unheralded syncope (not near syncope)
- Asymptomatic individual with an uninterpretable ECG that:
  - Has never been evaluated or
  - Is a new uninterpretable change.
- Individual with an elevated cardiac troponin.
- One routine study 2 years or more after a stent
  - Except with a left main stent where it can be done at 1 year.
- One routine study at 5 years or more after CABG, without cardiac symptoms.
- Every 2 years if there was documentation of previous “silent ischemia” on the imaging portion of a stress test but not on the ECG portion.
- To assess for CAD prior to starting a Class IC antiarrhythmic agent (flecainide or propafenone) and annually while taking the medication.
- Prior anatomic imaging study (coronary angiogram or CCTA) demonstrating coronary stenosis in a major coronary branch, which is of uncertain functional significance, can have one stress test with imaging.

- Evaluating new, recurrent, or worsening left ventricular dysfunction/CHF See CD-9.1: CHF– Imaging for additional indications.

**CD-1.5: Stress Testing with Imaging – Preoperative**

- There are 2 steps that determine the need for imaging stress testing in (stable) preoperative individuals:
  - Would the individual qualify for imaging stress testing independent of planned surgery?
    - If yes, proceed to stress testing guidelines;
    - If no, go to step 2
  - Is the surgery considered high, moderate or low risk? (See Table 2) If high or moderate-risk, proceed below. If low-risk, there is no evidence to determine a need for preoperative cardiac testing.
    - **High Risk Surgery**: All individuals in this category should receive an imaging stress test if there has not been an imaging stress test within 1 year*, unless the individual has developed new cardiac symptoms or a new change in the EKG since the last stress test.
    - **Intermediate Surgery**: One or more risk factors and unable to perform an ETT per guidelines if there has not been an imaging stress test within 1 year* unless the individual has developed new cardiac symptoms or a new change in the EKG since the last stress test.
    - **Low Risk**: Preoperative imaging stress testing is not supported.
  - Clinical Risk Factors (for cardiac death & non-fatal MI at time of non-cardiac surgery)
    - Planned high risk surgery (open surgery on the aorta or open peripheral vascular surgery)
    - History of ischemic heart disease (previous MI, previous positive stress test, use of nitroglycerin, typical angina, ECG Q waves, previous PCI or CABG)
- History of compensated previous congestive heart failure (history of heart failure, previous pulmonary edema, third heart sound, bilateral rales, chest x-ray showing heart failure)
- History of previous TIA or stroke
- Diabetes Mellitus
- Creatinine level >2 mg/dL

*Time interval is based on consensus of eviCore executive cardiology panel.

**Table 2**

<table>
<thead>
<tr>
<th>Cardiac Risk Stratification List</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High Risk (&gt;5%)</strong></td>
</tr>
<tr>
<td>➢ Open aortic and other</td>
</tr>
<tr>
<td>major open vascular surgery</td>
</tr>
<tr>
<td>➢ Open peripheral vascular</td>
</tr>
<tr>
<td>surgery</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**CD-1.6: Transplant Individuals**

- Stress Testing in individuals for Non-Cardiac Transplant
  - Individuals who are candidates for any type of organ bone marrow or stem cell transplant can undergo imaging stress testing every year (usually stress echo or MPI) prior to transplant.
  - Individuals who have undergone organ transplant are at increased risk for ischemic heart disease secondary to their medication. Risk of vasculopathy is 7% at one year, 32% at five years and 53% at ten years. An imaging stress test can be repeated annually after transplant for at least two years or within one year of a prior cardiac imaging study if there is evidence of progressive vasculopathy.
  - After two consecutive normal imaging stress tests, repeated testing is not supported more often than every other year without evidence for progressive vasculopathy or new symptoms.
  - Stress testing after five years may proceed according to normal patterns of consideration.

- Post-Cardiac transplant assessment of transplant CAD:
  - ONE of the following imaging studies may be performed annually:
    - MPI
    - Stress ECHO
    - Stress MRI
    - Cardiac PET perfusion **with** coronary flow quantitation (CPT® 78491 or CPT® 78492)
CD-1.7: Non-imaging Heart Function and Cardiac Shunt Imaging

- Echocardiogram is the preferred method for cardiac shunt detection.
- Echocardiogram, MPI, MUGA study, cardiac MRI, cardiac CT, or cardiac PET to obtain ejection fraction depending on the clinical situation.

Background and Supporting Information

- Procedures reported with CPT® 78414 and CPT® 78428 are essentially obsolete and should not be performed in lieu of other preferred modalities.

CD-1.8: Section left intentionally blank

References


<table>
<thead>
<tr>
<th>CD-2: Echocardiography (ECHO)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-2.1: Transthoracic Echocardiography (TTE) – Coding</td>
<td>16</td>
</tr>
<tr>
<td>CD-2.2: Transthoracic Echocardiography (TTE) – Indications</td>
<td>17</td>
</tr>
<tr>
<td>CD-2.3: Frequency of Echocardiography Testing</td>
<td>19</td>
</tr>
<tr>
<td>CD-2.4: Transesophageal Echocardiography (TEE) – Coding</td>
<td>20</td>
</tr>
<tr>
<td>CD-2.5: Transesophageal Echocardiography (TEE) – Indications</td>
<td>22</td>
</tr>
<tr>
<td>CD-2.6: Stress Echocardiography (Stress Echo) – Coding</td>
<td>23</td>
</tr>
<tr>
<td>CD-2.7: Stress Echocardiography – Indications, other than ruling out CAD</td>
<td>23</td>
</tr>
<tr>
<td>CD-2.8: 3D Echocardiography – Coding</td>
<td>24</td>
</tr>
<tr>
<td>CD-2.9: 3D Echocardiography – Indications</td>
<td>24</td>
</tr>
<tr>
<td>CD-2.10: Myocardial strain imaging (CPT® 0399T)</td>
<td>24</td>
</tr>
<tr>
<td>CD-2.11: Myocardial contrast perfusion echocardiography (CPT® 0439T)</td>
<td>24</td>
</tr>
</tbody>
</table>
CD-2.1: Transthoracic Echocardiography (TTE) - Coding

<table>
<thead>
<tr>
<th>TTE CODES</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transthoracic Echocardiography</td>
<td></td>
</tr>
<tr>
<td>TTE for congenital cardiac anomalies, complete</td>
<td>93303</td>
</tr>
<tr>
<td>TTE for congenital cardiac anomalies, follow-up or limited</td>
<td>93304</td>
</tr>
<tr>
<td>TTE with 2-D, M-mode, Doppler and color flow, complete</td>
<td>93306</td>
</tr>
<tr>
<td>TTE with 2-D, M-mode, without Doppler or color flow</td>
<td>93307</td>
</tr>
<tr>
<td>TTE with 2-D, M-mode, follow-up or limited</td>
<td>93308</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Doppler Echocardiography</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doppler echo, pulsed wave and/or spectral display</td>
<td>+93320*</td>
</tr>
<tr>
<td>Doppler echo, pulsed wave and/or spectral display, follow-up or limited study</td>
<td>+93321*</td>
</tr>
<tr>
<td>Doppler echo, color flow velocity mapping</td>
<td>+93325</td>
</tr>
</tbody>
</table>

*CPT® 93320 and CPT® 93321 should not be requested or billed together.

<table>
<thead>
<tr>
<th>Transthoracic Echocardiography</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>C8921 TTE for congenital cardiac anomalies, complete</td>
<td>93303</td>
</tr>
<tr>
<td>C8922 TTE for congenital cardiac anomalies, follow-up or limited</td>
<td>93304</td>
</tr>
<tr>
<td>C8929 TTE with 2-D, M-mode, Doppler and color flow, complete</td>
<td>93306</td>
</tr>
<tr>
<td>C8923 TTE with 2-D, M-mode, without Doppler or color flow</td>
<td>93307</td>
</tr>
<tr>
<td>C8924 TTE with 2-D, M-mode, follow-up or limited</td>
<td>93308</td>
</tr>
</tbody>
</table>

C codes are unique temporary codes established by CMS. C codes were established for contrast echocardiography. Each echocardiography C code corresponds to a standard echo code (Class I CPT code) The C code and the matching CPT code should not both be approved.

<table>
<thead>
<tr>
<th>Investigational Codes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0399T Myocardial strain imaging (quantitative assessment of myocardial mechanics using image-based analysis of local myocardial dynamics) (List separately in addition to code for primary procedure)</td>
<td>Investigational</td>
</tr>
<tr>
<td>0439T Myocardial contrast perfusion echocardiography, at rest or with stress, for assessment of myocardial ischemia or viability</td>
<td>Investigational</td>
</tr>
</tbody>
</table>

- Complete transthoracic echocardiogram with spectral and color flow Doppler (CPT® 93306).
  - CPT® 93306 includes the Doppler exams, so CPT® codes 93320-93325 should **not** be assigned together with CPT® 93306.
  - Doppler codes (CPT® 93320, CPT® 93321, and CPT® 93325) are ‘add-on codes’ (as denoted by the + sign) and are assigned in addition to code for the primary procedure.
- For a 2D transthoracic echocardiogram without Doppler, report CPT® 93307.
- Limited transthoracic echocardiogram should be billed if the report does not “evaluate or document the attempt to evaluate” all of the required structures.
  - A limited transthoracic echocardiogram is reported with CPT® 93308.
CPT® 93321 (not CPT® 93320) should be reported with CPT® 93308 if Doppler is included in the study. CPT® 93325 can be reported with CPT® 93308 if color flow Doppler is included in the study.

A limited congenital transthoracic echocardiogram is reported with CPT® 93304.

Doppler echo may be used for evaluation of the following:
- Shortness of breath
- Known or suspected valvular disease
- Known or suspected hypertrophic obstructive cardiomyopathy
- Shunt detection

Providers performing echo on a pediatric individual, may not know what procedure codes they will be reporting until the initial study is completed.

If a congenital issue is found on the initial echo, a complete echo is reported with codes CPT® 93303, CPT® 93320, and CPT® 93325 because CPT® 93303 does NOT include Doppler and color flow mapping.

If no congenital issue is discovered, then CPT® 93306 is reported alone and includes 2-D, Doppler and color flow mapping.

Since providers may not know the appropriate code/s that will be reported at the time of the pre-authorization request, they may request all 4 codes (CPT® 93303, CPT® 93320, CPT® 93325, and CPT® 93306).

Post-service audits may be completed to ensure proper claims submission.

CPT® 76376 and CPT® 76377 are not unique to 3D Echo. These codes also apply to 3D rendering of MRI and CT studies. (See CD-2.8: 3D Echocardiography – Coding)

CPT® 93325 may also be used with fetal echocardiography.

**CD-2.2: Transthoracic Echocardiography (TTE) – Indications**

- TTE can be performed for the following:
  - New or worsening cardiac signs or symptoms, including, but not limited to:
    - Dyspnea
    - Chest pain
    - Palpitations
    - Syncope
    - Heart failure
    - Murmur
  - Hypertension – can be done once with initial evaluation
  - New signs or symptoms of cerebral ischemia or peripheral embolic event
  - Valve function and structure:
    - History and/or physical examination suggesting significant valvular disorder
    - Valve Surgery
      - If valve surgery is being considered can have TTE twice a year
      - Post surgery at 6 weeks to establish baseline, then one routine study (surveillance) 3 years or more after valve surgery (repair or prosthetic valve implantation).
      - TAVR follow-up may be approved at, 1 month, and at one year post-procedure and annually thereafter.
• A baseline post-op TTE is usually performed within one week after surgery. This baseline study may also be approved as an outpatient if not performed in the hospital prior to discharge.
• See CD 4.8: Transcatheter Aortic Valve Replacement (TAVR)
  - Mitral valve clip follow-up may be approved at 1 month, at 6 months, and at one year post-procedure

VENTRICULAR FUNCTION ASSESSMENT INCLUDING, BUT NOT LIMITED TO THE FOLLOWING:
- Chemotherapy induced cardiomyopathy See CD-12.1: Oncologic Indications for Cancer Therapeutics- Related Cardiac Dysfunction (CTRCD)
- Post myocardial infarction can be done once in follow-up. This should not be done less than 6 weeks post MI
- Evaluation prior to ICD/CRT placement, if baseline has not been established

CARDIAC STRUCTURE: WHEN THERE ARE NEW OR WORSENING CARDIAC SIGNS OR SYMPTOMS, SUGGESTING DISORDERS SUCH AS, BUT NOT LIMITED TO:
- Infiltrative diseases (e.g. sarcoid, amyloid)
- Ventricular septal defect (VSD)
- Papillary muscle rupture/dysfunction
- Hypertrophy including:
  - Asymmetric septal hypertrophy
  - Spade heart
  - Hypertensive concentric hypertrophy
  - Infiltrative hypertrophy
  - Pacemaker insertion complication
  - Pericardial effusion
  - Cardiac injury due to blunt chest trauma

CARDIAC DEFECTS OR MASSES
- Embolic source in individuals with recent Transient Ischemic Attack (TIA), stroke, or peripheral vascular emboli as an initial study before TEE.
- ASD repair or VSD repair:
  - Within the first year of surgery
  - Incomplete septal defect repair may be followed yearly
- Tumor evaluation including myxomas
- Clot detection
- Evaluation of adult congenital heart disease See PEDCD-2 Congenital Heart Disease in the Pediatric Cardiac Imaging Guidelines
  - Routine yearly surveillance of adult congenital heart disease is allowed following incomplete or palliative repair, with residual abnormality and without a change in clinical status.
  - Screening for the presence of bicuspid aortic valve is recommended for first-degree relatives of individuals with bicuspid aortic valve.
  - Screening of the ascending aorta in known or suspected connective tissue disease that predisposes to an aortic aneurysm or dissection (e.g., Marfan syndrome, hereditary forms of ascending aortopathy).
  - See CH-29: Thoracic Aorta in the Chest Imaging Guidelines
Inflammatory
- Pericardial effusion/pericardial disease including pericardial cysts
- Congenital heart disease
- Endocarditis including:
  - Fever or
  - Positive blood cultures indicating bacteremia or
  - A new murmur

Pacemaker insertion complication

Screening for first-degree relatives of individuals with hypertrophic cardiomyopathy (HCM)
- First-degree relatives who are 12 to 18 years old should be screened yearly for HCM by 2D-echocardiography and ECG.
- First-degree relatives who are older than age 18 should have 2D-echo and ECG every five years to screen for delayed adult-onset LVH.
- Systematic screening is usually not indicated for first-degree relatives who are younger than age 12 unless there is a high-risk family history or the child is involved in particularly intense competitive sports.
- Affected individuals identified through family screening or otherwise should be evaluated every 12 to 18 months with 2D-echo, Holter monitor, and blood pressure response during maximal upright exercise.

New abnormality on an EKG that has not been evaluated.

Thoracic aortic aneurysm/dissection See CH-29: Thoracic Aorta in the Chest Imaging Guidelines.

Individuals with BAVs and no demonstrable aortopathy may be followed every 3 years with TTE for the development of aortic enlargement

CD-2.3: Frequency of Echocardiography Testing

- Repeat routine echocardiograms are not supported (annually or otherwise) for evaluation of clinically stable syndromes.
- Every three years, when there is a history of:
  - Bicuspid aortic valve
  - Mild aortic or mitral stenosis
  - Prosthetic heart valve
- Once a year (when no change in clinical status), when there a history of:
  - Significant valve dysfunction, including moderate or severe regurgitation or stenosis
  - Significant valve deformity, such as thickened myxomatous valve or bileaflet prolapse, regardless of extent of regurgitation or stenosis
  - Hypertrophic cardiomyopathy See CD-2.2: Transthoracic Echocardiography (TTE) – Indications, CD-2.7: Stress Echocardiography – Indications, other than ruling out CAD
  - Chronic pericardial effusions
  - Left ventricular contractility/diastolic function prior to planned medical therapy for heart failure or to evaluate the effectiveness of on-going therapy
- Pre-operative aortic root dilatation (See CH-29.2: Thoracic Aortic Aneurysm (TAA) in the Chest Imaging Guidelines for postoperative frequency)
- Pulmonary hypertension (can be done more frequently with change in therapy)
- Systemic Scleroderma
- Prior TAVR

Anytime, without regard for the number or timing of previous ECHO studies, if there is a change in clinical status or new signs or symptoms such as:
- Cardiac murmurs
- Myocardial infarction or acute coronary syndrome
- Congestive heart failure (new or worsening)
  - New symptoms of dyspnea
  - Orthopnea
  - Paroxysmal nocturnal dyspnea
  - Edema
  - Elevated BNP
- Pericardial disease
- Stroke/transient ischemic attack
- Decompression illness
- Prosthetic valve dysfunction or thrombosis
- A history of prior cardiac transplant, per transplant center protocol

Background and Supporting Information

Decisions regarding routine echocardiographic follow-up should not be based on the degree of regurgitation alone, but should take into account associated structural valvular and cardiac abnormalities. For example: a structurally normal mitral valve with moderate mitral regurgitation by color flow Doppler and normal left atrial size, does not generally require routine echocardiographic follow-up. However, a thickened, myxomatous appearing mitral valve with bi-leaflet prolapse and only trivial or mild mitral regurgitation, should be followed echocardiographically at routine intervals.
**CD-2.4: Transesophageal Echocardiography (TEE) – Coding**

<table>
<thead>
<tr>
<th>Transesophageal Echocardiography</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEE with 2-D, M-mode, probe placement, image acquisition, interpretation and report</td>
<td>93312</td>
</tr>
<tr>
<td>TEE probe placement only</td>
<td>93313</td>
</tr>
<tr>
<td>TEE image acquisition, interpretation, and report only</td>
<td>93314</td>
</tr>
<tr>
<td>TEE for congenital anomalies with 2-D, M-mode, probe placement, image acquisition, interpretation and report</td>
<td>93315</td>
</tr>
<tr>
<td>TEE for congenital anomalies, probe placement only</td>
<td>93316</td>
</tr>
<tr>
<td>TEE for congenital anomalies, image acquisition, interpretation and report only</td>
<td>93317</td>
</tr>
<tr>
<td>TEE for monitoring purposes, ongoing assessment of cardiac pumping function on an immediate time basis</td>
<td>93318</td>
</tr>
</tbody>
</table>

**Doppler Echocardiography**:  

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Transesophageal Echocardiography</th>
</tr>
</thead>
<tbody>
<tr>
<td>93312</td>
<td>TEE with 2-D, M-mode, probe placement, image acquisition, interpretation and report</td>
</tr>
<tr>
<td>93315</td>
<td>TEE for congenital anomalies with 2-D, M-mode, probe placement, image acquisition, interpretation and report</td>
</tr>
<tr>
<td>93318</td>
<td>TEE for monitoring purposes, ongoing assessment of cardiac pumping function on an immediate time basis</td>
</tr>
</tbody>
</table>

- **The complete transesophageal echocardiogram** service, including both (1) probe (transducer) placement and (2) image acquisition/interpretation, is reported with CPT® 93312.  
  - Probe placement only is reported with CPT® 93313.  
  - The image acquisition/interpretation only is reported with CPT® 93314.
- Physicians assign codes CPT® 93312, CPT® 93313, and/or CPT® 93314 to report professional services if the test is performed in a hospital or other facility where the physician cannot bill globally.  
  - Modifier-26 (professional component) is appended to the appropriate code  
  - CPT® 93313 and CPT® 93314 should never be used together. If both services are provided, CPT® 93312 is reported.
- Hospitals should report TEE procedures using CPT® 93312 (the complete service). CPT® 93313 and CPT® 93314 are not used for hospital billing.
- Monitoring of individuals undergoing cardiac surgery is CPT® 93318.
CD-2.5: Transesophageal Echocardiography (TEE) – Indications

- Limited transthoracic echo window
- Assessing valvular dysfunction, especially mitral regurgitation, when TTE is inadequate.
- Pre-operative planning for cardiac surgery
- Embolic source or intracardiac shunting when TTE is inconclusive
  - **Examples:** atrial septal defect, ventricular septal defect, patent foramen ovale, aortic cholesterol plaques, thrombus in cardiac chambers, valve vegetations, tumor
- Embolic events when there is an abnormal TTE or a history of atrial fibrillation
  - Clarify atria/atrial appendage, aorta, mitral/aortic valve beyond the information that other imaging studies have provided
  - Cardiac valve dysfunction
    - Differentiation of tricuspid from bicuspid aortic valve
    - Congenital abnormalities
- Assessing for left atrial thrombus prior to cardioversion of atrial fibrillation.
- Prior to planned atrial fibrillation ablation/pulmonary vein isolation procedure.
- Repeat TEE studies are based upon findings in the original study and documentation of the way in which repeat studies will affect individual management
CD-2.6: Stress Echocardiography (Stress Echo) - Coding

<table>
<thead>
<tr>
<th>Stress Echocardiography</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echo, transthoracic, with (2D), includes M-mode, during rest and exercise stress test and/or pharmacologically induced stress, with report;*</td>
</tr>
<tr>
<td>Echo, transthoracic, with (2D), includes M-mode, during rest and exercise stress test and/or pharmacologically induced stress, with report: including performance of continuous electrocardiographic monitoring, with physician supervision*</td>
</tr>
</tbody>
</table>

Doppler Echocardiography:

<table>
<thead>
<tr>
<th>Doppler Echocardiography:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doppler echo, pulsed wave and/or spectral display**</td>
</tr>
<tr>
<td>Doppler echo, pulsed wave and/or spectral display, follow-up/limited study</td>
</tr>
<tr>
<td>Doppler echo, color flow velocity mapping**</td>
</tr>
</tbody>
</table>

*CPT® 93350 and CPT® 93351 do not include Doppler studies

*Doppler echo (CPT® +93320 and CPT® +93325), if performed, may be reported separately in addition to the primary SE codes: CPT® 93350 or CPT® 93351.

CD-2.7: Stress Echocardiography–Indications, other than ruling out CAD

See CD-1.4: Stress Testing with Imaging – Indications

- In addition to the evaluation of CAD, stress echo can be used to evaluate the following conditions:
  - Dyspnea on exertion (specifically to evaluate pulmonary hypertension)
  - Right heart dysfunction
  - Valvular heart disease, especially when the outcome would affect a therapeutic or interventional decision
  - Pulmonary hypertension, when the outcome will measure response to therapy and/or prognostic information
  - Hypertrophic cardiomyopathy
    - In an individual with a history of hypertrophic cardiomyopathy who has been previously evaluated with a stress echo, another stress echo may be appropriate if there are worsening symptoms or if there has been a therapeutic change (for example: change in medication, surgical procedure performed).
- In general spectral Doppler (CPT® 93320 or 93321) and color-flow Doppler (CPT® 93325) are necessary in the evaluation of the above conditions and can be added to the stress echo code.
CD-2.8: 3D Echocardiography – Coding

The procedure codes used to report 3D rendering for echocardiography are not unique to echocardiography and are the same codes used to report the 3D post processing work for CT, MRI, ultrasound and other tomographic modalities.

- **CPT® 76376**, not requiring image post-processing on an independent workstation, is the most common code used for 3D rendering done with echocardiography
- **CPT® 76377** requires the use of an independent workstation

CD-2.9: 3D Echocardiography – Indications

- **3D Echo Indications**
  - Echocardiography with 3-dimensional (3D) rendering is becoming universally available, yet its utility remains limited based on the current literature. Current indications include:
    - Left ventricular volume and ejection fraction assessment
    - Mitral valve anatomy specifically related to mitral valve stenosis
    - Guidance of transcatheter procedures

CD-2.10: Myocardial strain imaging (CPT® 0399T)

- Investigational See **CD-2.1: Transthoracic Echocardiography (TTE) – Coding**

CD-2.11: Myocardial contrast perfusion echocardiography (CPT® 0439T)

- Investigational See **CD-2.1: Transthoracic Echocardiography (TTE) – Coding**
References


### CD-3: Nuclear Cardiac Imaging

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-3.1: Myocardial Perfusion Imaging (MPI) – Coding</td>
<td>28</td>
</tr>
<tr>
<td>CD-3.2: MPI – Indications</td>
<td>28</td>
</tr>
<tr>
<td>CD-3.3: MUGA - Coding</td>
<td>29</td>
</tr>
<tr>
<td>CD-3.4: MUGA Study – Cardiac Indications</td>
<td>29</td>
</tr>
<tr>
<td>CD-3.5: MUGA Study - Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)</td>
<td>30</td>
</tr>
<tr>
<td>CD-3.6: Myocardial Sympathetic Innervation Imaging in Heart Failure</td>
<td>30</td>
</tr>
<tr>
<td>CD-3.7: Myocardial Tc-99m Pyrophosphate Imaging</td>
<td>31</td>
</tr>
<tr>
<td>CD-3.8: Cardiac Amyloidosis</td>
<td>31</td>
</tr>
</tbody>
</table>
### CD-3.1: Myocardial Perfusion Imaging (MPI) – Coding

#### Nuclear Cardiac Imaging Procedure Codes

<table>
<thead>
<tr>
<th>Myocardial Perfusion Imaging (MPI)</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPI, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)</td>
<td>78451</td>
</tr>
<tr>
<td>MPI, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection</td>
<td>78452</td>
</tr>
</tbody>
</table>

- The most commonly performed myocardial perfusion imaging are single (at rest or stress, CPT® 78451) and multiple (at rest and stress, CPT® 78452) SPECT studies.
  - Evaluation of the individual’s left ventricular wall motion and ejection fraction are routinely performed during MPI and are included in the code’s definition.
  - First pass studies, (CPT® 78481 and CPT® 78483), MUGA, (CPT® 78472 and CPT® 78473) and SPECT MUGA (CPT® 78494) should not be reported in conjunction with MPI codes.
  - Attenuation correction, when performed, is included in the MPI service by code definition. No additional code should be assigned for the billing of attenuation correction.

- **Multi-day Studies:** It is not appropriate to bill separately for the rest and stress segments of MPI even if performed on separate calendar dates. A single code is assigned to define the entire procedure on the date all portions of the study are completed.

- 3D rendering, (CPT® 76377), should not be billed in conjunction with MPI.

- Separate codes for such related services as treadmill testing (CPT® 93015 - CPT® 93018) and radiopharmaceuticals should be assigned in addition to MPI.

### CD-3.2: MPI – Indications

- See **CD-1.4: Stress Testing with Imaging - Indications**
CD-3.3: MUGA - Coding

Nuclear Cardiac Imaging Procedure Codes

<table>
<thead>
<tr>
<th>MUGA (Multi Gated Acquisition) – Blood Pool Imaging</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium; planar, single study at rest or stress,</td>
<td>78472</td>
</tr>
<tr>
<td>wall motion study plus ejection fraction, with or without quantitative processing</td>
<td></td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium; planar, multiple studies, wall motion</td>
<td>78473</td>
</tr>
<tr>
<td>study plus ejection fraction, at rest and stress, with or without additional</td>
<td></td>
</tr>
<tr>
<td>quantification</td>
<td></td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, wall motion study</td>
<td>78494</td>
</tr>
<tr>
<td>plus ejection fraction, with or without quantitative processing</td>
<td></td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium, single study, at rest, with right</td>
<td>+78496</td>
</tr>
<tr>
<td>ventricular ejection fraction by first pass technique (List separately in addition to</td>
<td></td>
</tr>
<tr>
<td>code for primary procedure) [Use in conjunction with CPT® 78472]</td>
<td></td>
</tr>
</tbody>
</table>

- The technique employed for a MUGA service guides the code assignment. CPT® 78472 is used for a planar MUGA scan at rest or stress, and CPT® 78473 for planar MUGA scans, multiple studies at rest and stress.
- The two most commonly performed MUGA scans are the studies defined by CPT® 78472 and SPECT MUGA, CPT® 78494.
- Planar MUGA studies (CPT® 78472 and CPT® 78473) should not be reported in conjunction with:
  ◆ MPI (CPT® 78451 - CPT® 78454)
  ◆ First pass studies (CPT® 78481 - CPT® 78483), and/or
  ◆ SPECT MUGA (CPT® 78494).
- CPT® +78496 is assigned only in conjunction with CPT® 78472.
  ◆ See CD-3.4: MUGA Study – Cardiac Indications
  ◆ This add-on code should not be performed as a routine protocol.

CD-3.4: MUGA Study – Cardiac Indications

MUGA (Multi Gated Acquisition) – Blood Pool Imaging Indications

- Echocardiography is the preferred method of following left ventricular systolic function. Indications below refer to scenarios in which MUGA may be performed rather than ECHO:
  ◆ Prior ECHO demonstrates impaired systolic function (EF <50%).
  ◆ Pre-existing left ventricular wall motion abnormalities from ischemic heart disease or ischemic or non-ischemic cardiomyopathies.
  ◆ ECHO is technically limited and prevents accurate assessment of LV function.
  ◆ AICD placement:
    ▪ MUGA to assess LV ejection fraction when there are conflicting results between other forms of testing and the issue is clinically relevant, eg. MPI LVEF is 80% and an echo EF is 30%, the MUGA would be appropriate.
    ▪ However, if the MPI LVEF is 80% and the echo EF is 50%, this would not be appropriate even though the difference is significant since the echo EF is still normal.
Congestive heart failure
- MUGA to measure response to cardiac medications for CHF if echocardiogram was performed and was technically difficult
- Previous low LV ejection fraction determination was <50% and receiving potentially cardiotoxic chemotherapy
- Documentation of other need for information given by MUGA that cannot be obtained by ECHO

**MUGA is NOT indicated for the following:**
- A prior MUGA is not a reason to approve another MUGA (it is not necessary to compare LVEF by the same modality)
- To resolve differences in ejection fraction measurements between ECHO and MPI *unless* there is clear documentation as to how quantitative measurement of LVEF will affect individual management (e.g. implantation of an AICD).
- LV ejection fraction measurement is variable and can vary by +/-5-10% without any accompanying change in clinical status. Normal physiologic changes in intravascular volume, catecholamine levels, fever, and medications are among the many factors which cause variation in LVEF in the absence of myocardial pathology.
- Right ventricular first pass study, (CPT® +78496), may be indicated if there is clear documentation of a concern regarding right ventricular dysfunction or overload.

**CD-3.5: MUGA Study - Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)**

See **CD-12.1: Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)**

**CD-3.6: Myocardial Sympathetic Innervation Imaging in Heart Failure**
- Markers have been developed, using radioactive iodine, in an attempt to image this increased myocardial sympathetic activity. Currently, AdreView™ (Iodine-123 meta-iodobenzylguanidine), is the only FDA-approved imaging agent available for this purpose. eviCore currently considers AdreView to be experimental and investigational.
- The AMA has established the following set of Category III codes to report these studies:
  - **0331T** - Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment
  - **0332T** - Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT.

**Background and Supporting Information**
- In heart failure, the sympathetic nervous system is activated in order to compensate for the decreased myocardial function. Initially this is beneficial however, long term this compensatory mechanism is detrimental and causes further damage.
CD-3.7: Myocardial Tc-99m Pyrophosphate Imaging

<table>
<thead>
<tr>
<th>MUGA (Multi Gated Acquisition) – Blood Pool Imaging</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial Imaging, infarct avid, planar, qualitative or quantitative</td>
<td>78466</td>
</tr>
<tr>
<td>Myocardial Imaging, infarct avid, planar, qualitative or quantitative with ejection fraction by first pass technique</td>
<td>78468</td>
</tr>
<tr>
<td>Myocardial Imaging, infarct avid, planar, qualitative or quantitative tomographic SPECT with or without quantification</td>
<td>78469</td>
</tr>
<tr>
<td>For a single planar imaging session alone (without a SPECT study), Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area</td>
<td>78800</td>
</tr>
<tr>
<td>For planar with SPECT, Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s) tomographic (SPECT). Note: When reporting CPT® 78803, planar imaging of a limited area or multiple areas should be included with the SPECT</td>
<td>78803</td>
</tr>
</tbody>
</table>

CD-3.8: Cardiac Amyloidosis

- Tc-99m pyrophosphate imaging may be used to identify cardiac amyloidosis (CPT® 78803). Chest SPECT and planar imaging may be used, as well as whole body imaging for identification of systemic ATTR (transthyretin) amyloidosis.

- For a single planar imaging session alone (without a SPECT study), report CPT® 78800 Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area

- Indications may include:
  - Individuals with heart failure and unexplained increase in left ventricular wall thickness.
  - African-Americans over the age of 60 years with heart failure, unexplained or with increased left ventricular wall thickness (>12 mm).
  - Individuals over the age of 60 years with unexplained heart failure with preserved ejection fraction.
  - Individuals, especially elderly males, with unexplained neuropathy, bilateral carpal tunnel syndrome or atrial arrhythmias in the absence of usual risk factors, and signs/symptoms of heart failure.
  - Evaluation of cardiac involvement in individuals with known or suspected familial amyloidosis.
  - Diagnosis of cardiac ATTR in individuals with CMR or echocardiography consistent with cardiac amyloidosis.
  - Individuals with suspected cardiac ATTR amyloidosis and contraindications to CMR such as renal insufficiency or an implantable cardiac device.¹⁴
References
<table>
<thead>
<tr>
<th>CD-4: Cardiac CT, Coronary CTA, and CT for Coronary Calcium (CAC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-4.1: Cardiac CT and CTA – General Information and Coding 34</td>
</tr>
<tr>
<td>CD-4.2: CT for Coronary Calcium Scoring (CPT® 75571) 35</td>
</tr>
<tr>
<td>CD-4.3: CCTA – Indications for CCTA 35</td>
</tr>
<tr>
<td>CD-4.4: CCTA – Additional Indications 36</td>
</tr>
<tr>
<td>CD-4.5: Fractional Flow Reserve by Computed Tomography 37</td>
</tr>
<tr>
<td>CD-4.6: CT Heart – Indications 38</td>
</tr>
<tr>
<td>CD-4.7: CT Heart for Congenital Heart Disease 38</td>
</tr>
<tr>
<td>CD-4.8: Transcatheter Aortic Valve Replacement (TAVR) 39</td>
</tr>
</tbody>
</table>
### Cardiac Imaging Procedure Codes

<table>
<thead>
<tr>
<th>Cardiac CT and CTA</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT Heart, without contrast, with quantitative evaluation of coronary calcium</td>
<td>75571</td>
</tr>
<tr>
<td>The code set for Cardiac CT and CCTA (CPT® 75572 - CPT® 75574), include quantitative and functional assessment (for example, calcium scoring), if performed</td>
<td></td>
</tr>
<tr>
<td>CPT® 75571 describes a non-contrast CT Heart with calcium scoring and should be reported only when calcium scoring is performed as a stand-alone procedure.</td>
<td></td>
</tr>
<tr>
<td>▶ Can be used to report a preliminary non-contrast scan which indicates an excessive amount of calcium such that the original scheduled study must be discontinued.</td>
<td></td>
</tr>
<tr>
<td>▶ CPT® 75571 should not be reported in conjunction with any of the contrast CT/CTA codes (CPT® 75572 - CPT® 75574).</td>
<td></td>
</tr>
<tr>
<td>CT, heart, with contrast, for evaluation of cardiac structure and morphology (including 3D image post-processing, assessment of cardiac function, and evaluation of venous structures, if performed).</td>
<td>75572</td>
</tr>
<tr>
<td>CT, heart, with contrast, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image post-processing, assessment of cardiac function, and evaluation of venous structures, if performed).</td>
<td>75573</td>
</tr>
<tr>
<td>CTA, heart, coronary arteries and bypass grafts (when present), with contrast, including 3D image post-processing (including 3D image post-processing, assessment of cardiac function, and evaluation of venous structures, if performed).</td>
<td>75574</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission, analysis of fluid dynamics and simulated maximal coronary hyperemia, generation of estimated FFR model, with anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report</td>
<td>0501T</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission</td>
<td>0502T</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and generation of estimated FFR mode</td>
<td>0503T</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report</td>
<td>0504T</td>
</tr>
</tbody>
</table>
3D rendering, (CPT® 76377), should not be billed in conjunction with Cardiac CT and CCTA.

Only one code from the set: CPT® 75572 - CPT® 75574 can be reported per encounter.

CPT® 75574 includes evaluation of cardiac structure and morphology, when performed; therefore, additional code/s should not be assigned.

Background and Supporting Information

The high negative predictive value (98%-99%) of CCTA in ruling out significant coronary artery disease has been confirmed on multiple studies.

CD-4.2: CT for Coronary Calcium Scoring (CPT® 75571)

CD-4.2.1: CT Calcium Scoring for CAD Screening

Coronary calcium scoring as a standalone test is considered investigational in asymptomatic individuals with any degree of CAD risk.

Texas Heart Attack Preventive Screening Law (HR 1290) mandates that insurers in Texas cover either a calcium scoring study (CPT® 75571 or HCPCS S8092) or a carotid intima-media thickness study (ultrasound—Category III code 0126T) every five years for certain populations. To qualify, the following must apply:
  - Must be a Texas resident.
  - Must be a member of a fully-insured Texas health plan.
  - Must be a man age 45 to 75 or a woman age 55 to 75.
  - Must have either diabetes or a Framingham cardiac risk score of intermediate or higher.
  - Must not have had a calcium scoring study or a carotid intima-media thickness study within the past 5 years.

CD-4.2.2: CT Calcium Scoring Indications

Symptomatic individuals with a ‘very low’, or ‘low’ pretest probability of CAD*, See Table 1 in CD-1.1: General Issues – Cardiac

CD-4.3: CCTA – Indications for CCTA

Symptomatic individuals who have a ‘low’ or ‘intermediate’ pretest probability of CAD*, (See Table 1 in CD-1.1: General Issues – Cardiac):
  - ‘Low’ or ‘intermediate’ pre-test probability of coronary disease with persistent symptoms after a stress test.
  - Replace performance of invasive coronary angiogram in individuals with low risk of CAD (i.e. Pre-op non-coronary surgery).
  - For symptomatic individuals, evaluate post-CABG graft patency when only graft patency is a concern and imaging of the native coronary artery anatomy is not needed, such as in early graft failure.
CD-4.4: CCTA – Additional Indications

- Re-do CABG
  - To identify whether bypass grafts are located directly beneath the sternum, so that alternative ways to enter the chest can be planned.

- Evaluate coronary artery anomalies and other complex congenital heart disease of cardiac chambers or great vessels.
  - Report CPT® 75574 for evaluating coronary artery anomalies.
  - Report CPT® 75573 for congenital heart disease.
    - To evaluate the great vessels, Chest CTA (CPT® 71275) can be performed instead of CCTA or in addition to CCTA. For anomalous pulmonary venous return, can add CT Abdomen and Pelvis with contrast (CPT® 74177).

- Anomalous coronary artery(ies) suspected for diagnosis or to plan treatment and less than age 40 with a history that includes one or more of the following:
  - Persistent exertional chest pain and normal stress test,
  - Full sibling(s) with history of sudden death syndrome before age 30 or with documented anomalous coronary artery,
  - Resuscitated sudden death and contraindications for conventional coronary angiography.
  - Prior nondiagnostic coronary angiography in determining the course of the anomalous coronary artery in relation to the great vessels, origin of a coronary artery or bypass graft location.

- Unexplained new onset of heart failure.

- Evaluation of newly diagnosed congestive heart failure or cardiomyopathy.
  - No prior history of coronary artery disease, the ejection fraction is less than 50 percent, and low or intermediate risk on the pre-test probability assessment, and
  - No exclusions to cardiac CT angiography.
  - No cardiac catheterization, SPECT, cardiac PET, or stress echocardiogram has been performed since the diagnosis of congestive heart failure or cardiomyopathy.

- Ventricular tachycardia (6 beat runs or greater) if CCTA will replace conventional invasive coronary angiography.

- Equivocal coronary artery anatomy on conventional cardiac catheterization.

- Newly diagnosed dilated cardiomyopathy.

- Preoperative assessment of the coronary arteries in individuals who are going to undergo surgery for aortic dissection, aortic aneurysm, or valvular surgery if CCTA will replace conventional invasive coronary angiography.

- Vasculitis/Takayasu’s/Kawasaki’s disease

- **Cardiac Trauma:** Chest CTA (CPT® 71275) and CCTA (CPT® 75574) are useful in detecting aortic and coronary injury and can help in the evaluation of myocardial and pericardial injury (See **CD-10.1: Cardiac Trauma – Imaging**).
Relative contraindications for Coronary CT

- Irregular heart rhythms (e.g., atrial fibrillation/flutter, frequent irregular premature ventricular contractions or premature atrial contractions, and high grade heart block)
- Multifocal Atrial Tachycardia (MAT)
- Inability to lie flat
- Body mass index of 40 or more
- Inability to obtain a heart rate less than 65 beats per minute after beta-blockers
- Inability to hold breath for at least 8 seconds
- Renal Insufficiency
- Asymptomatic individuals and routine use in the evaluation of the coronary arteries following heart transplantation
- CCTA should not be performed if there is extensive coronary calcification (calcium score >1000).
- Evaluation of coronary stent patency if the vessel is less than 3.0 mm in diameter (metal artifact limits accuracy)
- Evaluation of left ventricular function following myocardial infarction or in chronic heart failure
  - Individuals with indeterminate echocardiogram should undergo MUGA (CPT® 78472 or CPT® 78494) or cardiac MRI.
- High pre-test probability for CAD – rather, these individuals should undergo conventional coronary angiography, especially if an interventional procedure (e.g., PCI) is anticipated.
- Identification of plaque composition and morphology
- Myocardial perfusion and viability studies
- Preoperative assessment for non-cardiac, nonvascular surgery
- Routine follow-up of asymptomatic or stable symptoms of CAD with CCTA
- There is insufficient evidence to support routine use of Coronary Computed Tomography Angiography (CCTA) in the evaluation of the coronary arteries following heart transplantation.

CD-4.5: Fractional Flow Reserve by Computed Tomography

- Fractional flow reserve (FFR) is typically measured using invasive techniques. FFR can be obtained noninvasively from coronary computed tomography angiography data (FFR-CT).
- Indications for FFR-CT
  - To further assess CAD seen on a recent CCTA that is of uncertain physiologic significance
CD-4.6: CT Heart – Indications

- Cardiac vein identification for lead placement in individuals needing left ventricular pacing.
- Pulmonary vein isolation procedure (ablation) for atrial fibrillation
  - Cardiac MRI (CPT® 75557 or CPT® 75561), chest MRV (CPT® 71555), chest CTV (CPT® 71275), or cardiac CT (CPT® 75572) can be performed to evaluate anatomy of the pulmonary veins prior to an ablation procedure performed for atrial fibrillation.
  - Study may be repeated post-procedure between 3-6 months after ablation because of a 1%-2% incidence of asymptomatic pulmonary vein stenosis.
  - See CD-8: Pulmonary Artery and Vein Imaging
- If echocardiogram is inconclusive for:
  - Cardiac or pericardial tumor or mass
  - Cardiac thrombus
  - Pericarditis/constrictive pericarditis
  - Complications of cardiac surgery
- Clinical suspicion of arrhythmogenic right ventricular dysplasia or arrhythmogenic cardiomyopathy (ARVD/ARVC), especially if an individual has presyncope or syncope if the clinical suspicion is supported by established criteria for ARVD.
- Recurrent laryngeal nerve palsy due to cardiac chamber enlargement.
- Coronary imaging is not included in the code definition for CPT® 71275.
  - The AMA definition for CPT® 71275 reads: “CTA Chest (non-coronary), with contrast material(s), including non-contrast images, if performed, and image post-processing.”

CD-4.7: CT Heart for Congenital Heart Disease

- Coronary artery anomaly evaluation
  - Cardiac catheterization was performed, and not all coronary arteries were identified.
- Thoracic arteriovenous anomaly evaluation
  - Cardiac MRI or chest CT angiogram was performed and suggested congenital heart disease.
- Complex adult congenital heart disease evaluation
  - No cardiac CT or cardiac MRI has been performed, and there is a contraindication to cardiac MRI.
  - Cardiac CT or cardiac MRI was performed one year ago or more.
CD-4.8: Transcatheter Aortic Valve Replacement (TAVR)

Once the decision has been made for aortic valve replacement, the following may be used to determine if an individual is a candidate for TAVR:

- CTA Chest (CPT® 71275), Abdomen and Pelvis (combination code CPT® 74174), and ONE of the following:
  - Cardiac CT (CPT® 75572) to measure the aortic annulus ² or
  - Coronary CTA (CCTA CPT® 75574) to both measure the aortic annulus and assess the coronary arteries in lieu of heart catheterization.

Post TAVR:
- TAVR follow-up may be approved at 1 month, at one year post-procedure, and annually thereafter.

A baseline post-op TTE is usually performed within one week after surgery. This baseline study may also be approved as an outpatient if not performed in the hospital prior to discharge.

References


| CD-5.1: Cardiac MRI – Coding               | 42  |
| CD-5.2: Cardiac MRI – Indications (excluding Stress MRI) | 42  |
| CD-5.3: Cardiac MRI – Indications for Stress MRI        | 44  |
| CD-5.4: Cardiac MRI – Aortic Root and Proximal Ascending Aorta | 44  |
| CD-5.5: Cardiac MRI – Evaluation of Pericardial Effusion or Diagnosis of Pericardial Tamponade | 44  |
CD-5.1: Cardiac MRI – Coding

<table>
<thead>
<tr>
<th>Cardiac Imaging Procedure Codes</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast</td>
<td>75557</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast; with stress imaging</td>
<td>75559</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without and with contrast and further sequences</td>
<td>75561</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without and with contrast and further sequences; with stress imaging</td>
<td>75563</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure)</td>
<td>+75565</td>
</tr>
</tbody>
</table>

- Only one procedure code from the set (CPT® 75557 - CPT® 75563) should be reported per session.
- Only one flow velocity measurement (CPT® +75565) should be reported per session when indicated.
  - Requests for cardiac MRI that contain more than one cardiac/chest MRI CPT® Code must be forwarded for Medical Director Review.

CD-5.2: Cardiac MRI – Indications (excluding Stress MRI)

- For additional cardiac MRI indications, See:
  - CD-4.4: CCTA – Additional Indications - relative contraindications for Cardiac/Coronary CT
  - CD-8: Pulmonary Artery and Vein Imaging
  - CD-9: Congestive Heart Failure
  - CD-10.1: Cardiac Trauma - Imaging

- Assess myocardial viability (to differentiate hibernating myocardium from scar) when necessary to determine if revascularization should be performed (CPT® 75561)

- Assessment of global ventricular function and mass if a specific clinical question is left unanswered by a recent echocardiogram and results will affect individual management (CPT® 75557 or CPT® 75561). Particularly useful in evaluating:
  - Cardiomyopathy (ischemic, diabetic, hypertrophic, or muscular dystrophy)
  - Noncompaction
  - Amyloid heart disease
  - Post cardiac transplant
  - Hemochromatosis
  - Post transfusion hemosiderosis
  - Hypertrophic heart disease
  - Myocarditis, cardiac aneurysm, trauma and contusions
  - Monitoring cancer chemotherapy effect on the heart (especially if accurate assessment of right ventricular function is documented as necessary).
> Pre and postoperative congenital heart disease assessment (e.g. Tetralogy of Fallot, patent ductus arteriosus, platypnea, atrial septal defects, restrictive VSD, anomalous pulmonary arteries or veins or anomalous coronary arteries) (CPT® 75557 or CPT® 75561).
  > Chest MRA (CPT® 71555) may be added if the aorta or pulmonary artery need to be visualized beyond the root.
  > Report CPT® +75565 in conjunction with CPT® 75557 or CPT® 75561, only if there is a need to clarify findings on a recent echocardiogram and cardiac Doppler study.
> Chest MRA alone (CPT® 71555) can be performed in certain situations (e.g. suspected dissection, coarctation, known or suspected aortic aneurysm).
> Coarctation of the aorta
  > Follow-up (surveillance) imaging after repair of coarctation:
    > Adults: chest MRA (CPT® 71555) every 2 to 3 years and before and after any intervention for re-coarctation
    > Infants and children: ECHO every month for several months, then ECHO every 6 months to one year thereafter
> Arrhythmogenic right ventricular dysplasia or arrhythmogenic cardiomyopathy (ARVD/ARVC) suspicion (including presyncope or syncope, established criteria for ARVD (CPT® 75557 or CPT® 75561).
> Differentiate constrictive pericarditis from restrictive cardiomyopathy (CPT® 75561).
> Evaluate cardiac tumor or mass when echocardiogram is inconclusive.
> Initial evaluation for cardiac sarcoidosis.
> Anomalous coronary arteries: Cardiac MRI (CPT® 75561) or CCTA (CPT® 75574) is much better at detecting this than conventional angiography.
> Assess coronary arteries in Kawasaki’s disease.
> Fabry disease
  > Late enhancement MRI may predict the effect of enzyme replacement therapy on myocardial changes that occur with this disease (CPT® 75561).
> Evaluate valvular heart disease when echocardiogram is inconclusive:
  > CPT® 75557 or CPT® 75561 and
  > CPT® 75565
> Cardiac MRI (CPT® 75557 or CPT® 75561) or chest MRV (CPT® 71555), but not both (See CD-8: Pulmonary Artery and Vein Imaging for guidelines on follow-up imaging after ablation procedure) for pulmonary vein anatomy for planned ablation procedures in individuals with atrial fibrillation.
> Suspected cardiac thrombus when echocardiogram is inconclusive (CPT® 75557).
> Right ventricular function evaluation (CPT® 75557 in conjunction with CPT® +75565) if a recent ECHO has been done, and there is documented need to perform cardiac MRI in order to resolve an unanswered question.
Shunting through a VSD (CPT® 75557 in conjunction with CPT® +75565) if a recent ECHO has been done, including a bubble study, and there is documented need to perform cardiac MRI in order to resolve an unanswered question.

Evaluate for iron overload due to conditions requiring frequent blood transfusions (i.e. sickle cell, thalassemia, hemochromatosis, etc.) (CPT® 75557).

**CD-5.3: Cardiac MRI – Indications for Stress MRI**

- For indications for Stress MRI, See **CD-1.4: Stress Testing with Imaging - Indications**
- If a nuclear perfusion (MPI) stress test was performed and was equivocal, a stress MRI is appropriate.

**CD-5.4: Cardiac MRI - Aortic Root and Proximal Ascending Aorta**

- See **CH-29: Thoracic Aorta** in the Chest Imaging Guidelines

**CD-5.5: Cardiac MRI - Evaluation of Pericardial Effusion or Diagnosis of Pericardial Tamponade**

- Contrast enhanced cardiac MRI (CPT® 75561) is useful for evaluating pericarditis, neoplastic and other effusion, tamponade or myocardial infiltration if a specific clinical question is left unanswered by echocardiogram or another recent imaging study.
References


### CD-6: Cardiac PET

| CD-6.1: Cardiac PET – Coding | 47 |
| CD-6.2: Cardiac PET – Perfusion - Indications (CPT® 78491 and CPT® 78492) | 47 |
| CD-6.3: Cardiac PET – Absolute Quantitation of Myocardial Blood Flow (CPT® 0482T) | 47 |
| CD-6.4: Cardiac PET – Metabolic – Indications (CPT® 78459) | 47 |
CD-6.1: Cardiac PET – Coding

<table>
<thead>
<tr>
<th>CARDIAC PET</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial imaging, PET, <em>metabolic</em> evaluation</td>
<td>78459</td>
</tr>
<tr>
<td>Myocardial imaging, PET, <em>perfusion</em>; single study at rest or stress</td>
<td>78491</td>
</tr>
<tr>
<td>Myocardial imaging, PET, <em>perfusion</em>; multiple studies at rest and/or stress</td>
<td>78492</td>
</tr>
<tr>
<td>Absolute quantitation of myocardial blood flow, PET, rest and stress</td>
<td>+0482T</td>
</tr>
</tbody>
</table>

- 3D rendering, (CPT® 76377), should not be billed in conjunction with PET.
- Separate codes for such related services as treadmill testing (CPT® 93015 - CPT® 93018) and radiopharmaceuticals should be assigned in addition to perfusion PET.
- 0482T is an add on code for CPT® 78491 or CPT® 78492 and is considered investigational

CD-6.2: Cardiac PET – Perfusion – Indications (CPT® 78491 and CPT® 78492)

- Meets all of the criteria for an imaging stress test and additionally any one of the following:
  - Individual is obese (for example BMI >40 kg/m²) or
  - Individual has large breasts or implants
- Equivocal nuclear perfusion (MPI) stress test
  - Routine use in post heart transplant assessment of transplant CAD

CD-6.3: Cardiac PET – Absolute Quantitation of Myocardial Blood Flow (CPT® 0482T)*

- Performance of quantitation of myocardial blood flow by Cardiac PET is currently non-standardized between different vendor products.
- Absolute quantitation of myocardial blood flow is considered experimental, investigational and/or unproven (EIU).

*Code reviewed by eviCore for Cigna

CD-6.4: Cardiac PET – Metabolic – Indications (CPT® 78459)

- To determine myocardial viability when a previous study has shown significant left ventricular dysfunction when under consideration for revascularization, or
- To identify and monitor response to therapy for established or strongly suspected cardiac sarcoid. This study may be performed in conjunction with a Cardiac PET perfusion examination, single study, CPT® 78491 or MPI SPECT CPT® 78451
References
## CD-7: Diagnostic Heart Catheterization

<table>
<thead>
<tr>
<th>CD-7.1: Diagnostic Heart Catheterization – Code Sets</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-7.2: Diagnostic Heart Catheterization – Coding Notes</td>
<td>51</td>
</tr>
<tr>
<td>CD-7.3: Diagnostic Left Heart Catheterization (LHC)</td>
<td>51</td>
</tr>
<tr>
<td>CD-7.4: Right Heart Catheterization (RHC)</td>
<td>53</td>
</tr>
<tr>
<td>CD-7.5: Combined Right and Left Heart Catheterization</td>
<td>54</td>
</tr>
<tr>
<td>Indications</td>
<td></td>
</tr>
<tr>
<td>CD-7.6: Planned (Staged) Coronary Interventions</td>
<td>54</td>
</tr>
</tbody>
</table>
## CD-7.1: Diagnostic Heart Catheterization – Code Sets

<table>
<thead>
<tr>
<th>Cardiac Cath Procedures</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital Heart Disease Code “Set”</td>
<td>93530-93533</td>
</tr>
<tr>
<td>Right Heart Catheterization (CHD)</td>
<td>93530</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CHD)</td>
<td>93531</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CHD-TS)</td>
<td>93532</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CAD-ASD)</td>
<td>93533</td>
</tr>
<tr>
<td>Anomalous coronary arteries, patent foramen ovale, mitral valve prolapse, and bicuspid aortic valve</td>
<td>93451-93464, 93566-93568</td>
</tr>
<tr>
<td>RHC without LHC or coronaries</td>
<td>93451</td>
</tr>
<tr>
<td>LHC without RHC or coronaries</td>
<td>93452</td>
</tr>
<tr>
<td>RHC and retrograde LHC without coronaries</td>
<td>93453</td>
</tr>
<tr>
<td>Native coronary artery catheterization;</td>
<td>93454</td>
</tr>
<tr>
<td>with bypass grafts</td>
<td>93455</td>
</tr>
<tr>
<td>with RHC</td>
<td>93456</td>
</tr>
<tr>
<td>with RHC and bypass grafts</td>
<td>93457</td>
</tr>
<tr>
<td>with LHC</td>
<td>93458</td>
</tr>
<tr>
<td>with LHC and bypass grafts</td>
<td>93459</td>
</tr>
<tr>
<td>with RHC and LHC</td>
<td>93460</td>
</tr>
<tr>
<td>with RHC and LHC and bypass grafts</td>
<td>93461</td>
</tr>
<tr>
<td>LHC by transseptal or apical puncture</td>
<td>+93462</td>
</tr>
<tr>
<td>Angiography of noncoronary arteries and veins, performed as a distinct service</td>
<td>Select appropriate codes from the Radiology and Vascular Injection Procedures sections.</td>
</tr>
</tbody>
</table>
CD-7.2: Diagnostic Heart Catheterization – Coding Notes

Cardiac catheterization (CPT® 93451-CPT® 93461) includes all “road mapping” angiography necessary to place the catheters, including any injections and imaging supervision, interpretation, and report.

Cardiac catheterization (CPT® 93452-CPT® 93461) (for all conditions other than congenital heart disease) includes contrast injections, imaging supervision, interpretation, and report for imaging typically performed.

Catheter placements in native coronaries or bypass grafts (CPT® 93454-CPT® 93461) include intraprocedural injections for bypass graft angiography, imaging supervision, and interpretation.

Injection codes CPT® 93563-CPT® 93565 should not be used in conjunction with CPT® 93452-CPT® 93461.

Codes CPT® 93451-CPT® 93461 do not include contrast injections and imaging supervision, interpretation, and report for imaging that is separately identified by the following specific procedure codes: CPT® 93566, CPT® 93567 and CPT® 93568.

Separate diagnostic cardiac catheterization codes should only be assigned in conjunction with interventional procedures in the following circumstances:

- No prior or recent diagnostic catheterization is available to guide therapy
- Individual’s condition has significantly changed since the last diagnostic cath
- The treatment plan may be affected
- Other vessels may be identified for treatment
- Further establishment of a diagnosis from a non-invasive study is necessary

CD-7.3: Diagnostic Left Heart Catheterization (LHC)

- These guidelines apply to individuals with stable conditions and who are not in the acute setting (acute coronary syndrome) or individuals with unstable angina. Individuals in acute settings or with unstable angina should be handled as medical emergencies.

- Incidental angiography can be performed:
  - Iliac/femoral artery angiography when dissection or obstruction to the passage of the catheter/guidewire is encountered.
  - Renal arteriography if criteria outlined in the PVD Imaging Guidelines are met (See PVD-6.5: Renovascular Hypertension in the Peripheral Vascular Disease (PVD) Imaging Guidelines).

- Identifying disease for which invasive procedures have been shown to prolong survival:
  - Left main coronary artery disease plus right coronary artery disease plus left ventricular dysfunction.
  - Triple vessel coronary artery disease plus left ventricular dysfunction.

- Unstable angina (new, accelerating, or worsening symptoms that are suggestive of unstable angina), even in the absence of noninvasive cardiac testing.
Symptomatic individuals with a high pretest probability of CAD.

Angina that is unresponsive to optimized medical therapy (See CD-1.1: General Issues – Cardiac) and for which invasive procedures are needed to provide pain relief.

Left ventricular dysfunction (congestive heart failure) in individuals suspected of having coronary artery disease.

Ventricular fibrillation or ventricular tachycardia where the etiology is unclear.

Unheralded syncope (not near syncope).

Recent noninvasive cardiac testing was equivocal, unsuccessful in delineating the clinical problem, or led to a conclusion that intervention is indicated for the following conditions:

- Suspicion of cardiomyopathy, endocarditis, or myocarditis
- Significant/serious ventricular arrhythmia
- Evaluating progression of known CAD when symptoms are persistent or worsening
- An intermediate or large amount of myocardium (>5%) may be in jeopardy
- Evaluation of coronary grafts
- Evaluation of previously placed coronary artery stents
- Evaluation of structural disease

Ruling out coronary artery disease prior to planned non-coronary cardiac or great vessel surgery (i.e. cardiac valve surgery, aortic dissection, aortic aneurysm, congenital disease repair such as atrial septal defect, etc.).

Assessment for accelerated coronary artery disease associated with cardiac transplantation.

Pre-organ transplant (non-cardiac). Some institutions perform a heart cath as part of their initial evaluation protocol. Others use an imaging stress test for evaluation. Either is appropriate and can be approved but NOT both.

Valvular heart disease when there is a discrepancy between the clinical findings (history, physical exam, and non-invasive test results) or valvular surgery is being considered.

Suspected pericardial disease.

A history of prior cardiac transplant, per transplant center protocol
**CD-7.4: Right Heart Catheterization (RHC)**

**CD-7.4.1: General information RHC**
- It is performed most commonly from the femoral vein, less often through the subclavian or internal jugular veins and interatrial septal puncture approach.
- It includes a full oximetry for detection and quantification of shunts.
- Pressure measurements are made and are done simultaneously with aortic and left ventricular pressures.
- Cardiac outputs are calculated by several techniques including thermodilution.

**CD-7.4.2: Diagnostic Right Heart Catheterization – Indications**
- Atrial septal defect (ASD) including shunt detection and quantification
- Ventricular septal defect (VSD) including shunt detection and quantification
- Patent foramen ovale (PFO)
- Anomalous pulmonary venous return
- Congenital defects including persistent left vena cava
- Pulmonary hypertension
- Pericardial diseases (constrictive or restrictive pericarditis)
- Valvular disease
- Right heart failure
- Left heart failure
- Preoperative evaluation for valve surgery
- Newly diagnosed or worsening cardiomyopathy
- During a left heart cath where the etiology of the symptoms remains unclear.
- Pre-lung transplant to assess pulmonary pressures
- Uncertain intravascular volume status with an unclear etiology
- Assessment post cardiac transplant
  - For routine endomyocardial biopsy
  - Assess for rejection
  - Assess pulmonary artery pressure
  - Can be done per the institution protocol or anytime organ rejection is suspected and biopsy is needed for assessment
- Evaluation of right ventricular morphology.
- Suspected arrhythmogenic right ventricular dysplasia.
CD-7.5: Combined Right and Left Heart Catheterization Indications

- Preoperative evaluation for valve surgery
- Newly diagnosed or worsening cardiomyopathy
- If the major component of the individual’s symptoms is dyspnea, and the indications for **CD-7.3: Diagnostic Left Heart Catheterization (LHC)** are also met
- If indications are met according to **CD-7.3: Diagnostic Left Heart Catheterization (LHC)** and **CD-7.4: Right Heart Catheterization (RHC)**, then a combination heart catheterization may be appropriate.

CD-7.6: Planned (Staged) Coronary Interventions

- The CPT® codes for percutaneous coronary interventions (PCI) include the following imaging services necessary for the procedure(s):
  - Contrast injection, angiography, ‘roadmapping’, and fluoroscopic guidance
  - Vessel measurement
  - Angiography following coronary angioplasty, stent placement, and atherectomy
- Separate codes for these services should not be assigned in addition to the PCI code/s because the services are already included.
- A repeat diagnostic left heart catheterization is not medically necessary when the individual is undergoing a planned staged percutaneous coronary intervention.
- CPT® 93530 to 93533 are appropriate for invasive evaluation of congenital heart disease.
References
# CD-8: Pulmonary Artery and Vein Imaging

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-8.1</td>
<td>Pulmonary Artery Hypertension (PAH) - Indications</td>
<td>57</td>
</tr>
<tr>
<td>CD-8.2</td>
<td>Pulmonary Vein Imaging - Indications</td>
<td>57</td>
</tr>
</tbody>
</table>
CD-8.1: Pulmonary Artery Hypertension (PAH) - Indications

- CT or CTA or MRA pulmonary arteries (CPT® 71260 or CPT® 71275 or CPT® 71555) is useful in the assessment of PAH, especially if there is suspicion for recurrent pulmonary emboli.
- In the absence of a clinical change, follow-up imaging for PAH is not indicated.
- See
  - PVD-5: Pulmonary Artery Hypertension in the Peripheral Vascular Disease Imaging Guidelines.
  - CH-25: Pulmonary Embolism (PE) in the Chest Imaging Guidelines.

CD-8.2: Pulmonary Vein Imaging – Indications

- MRI Cardiac (CPT® 75557 or CPT® 75561), MRV Chest (CPT® 71555), CTV Chest (CPT® 71275), or CT Cardiac (CPT® 75572) to evaluate anatomy of the pulmonary veins:
  - Prior to an ablation procedure performed for atrial fibrillation.
  - Post-procedure between 3-6 months after ablation because of a 1% to 2% incidence of asymptomatic pulmonary vein stenosis.
    - If no pulmonary vein stenosis is present, no further follow-up imaging is required.
    - If pulmonary vein stenosis is present on imaging following ablation and symptoms of pulmonary vein stenosis (usually shortness of breath) are present, can be imaged at 1, 3, 6, and 12 months.

Background and Supporting Information

- The majority (81%) of pulmonary vein stenosis remain stable over 1 year. Progression occurs in 8.8% and regression occurs in a small percentage.
References


<table>
<thead>
<tr>
<th>CD-9: Congestive Heart Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CD-9.1: CHF – Imaging</strong></td>
</tr>
<tr>
<td><strong>CD-9.2: Section left intentionally blank</strong></td>
</tr>
<tr>
<td><strong>CD-9.3: Myocardial Sympathetic Innervation Imaging</strong></td>
</tr>
</tbody>
</table>
**CD-9.1: CHF – Imaging**

- Congestive heart failure, including post-cardiac transplant failure:
  - Echocardiogram is the first study to be done after the clinical evaluation of the individual who is suspected of having heart failure.
  - MUGA, cardiac MRI or cardiac CT may be indicated if the ECHO is limited or does not completely answer the question.
  - Stress test to assess for CAD may be indicated. Follow stress testing guideline: [CD-1.4: Stress Testing with Imaging - Indications](#)

- Arteriovenous fistula with “high output” heart failure:
  - CT Chest with contrast (CPT® 71260 ) and/or CT Abdomen and/or CT Pelvis with contrast (CPT® 74160 or CPT® 72193 or CPT® 74177) OR
  - CTA Chest (CPT® 71275 ) and/or CTA Abdomen and/or CTA Pelvis (CPT® 74175 or CPT® 72191 or CPT® 74174) OR
  - MRI Chest and/or MRI Abdomen and/or MRI Pelvis without and with contrast (CPT® 71552 and/or CPT® 74183 and/or CPT® 72197) OR
  - MRA Chest and/or MRI Abdomen and/or MRI Pelvis (CPT® 71555 and/or CPT® 74185 and/or CPT® 72198)

- Right-sided congestive heart failure can be a manifestation of pulmonary hypertension or serious lung disease.
  - CT Chest (CPT® 71260) or CTA Chest (CPT® 71275) to evaluate for recurrent pulmonary embolism

**CD-9.2: This section left intentionally blank**

**CD-9.3: Myocardial Sympathetic Innervation Imaging**

- Markers have been developed, using radioactive iodine, in an attempt to image this increased myocardial sympathetic activity. Currently, AdreView™ (Iodine-123 meta-iodobenzylguanidine), is the only FDA-approved imaging agent available for this purpose. eviCore currently considers AdreView™ to be experimental and investigational.

- The AMA has established the following set of Category III codes to report these studies:
  - 0331T - Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment
  - 0332T - Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT.

**Background and Supporting Information**

- In heart failure, the sympathetic nervous system is activated in order to compensate for the decreased myocardial function. Initially this is beneficial however, long term this compensatory mechanism is detrimental and causes further damage.
References
**CD-10.1: Cardiac Trauma – Imaging**

ANY of the following can be used to evaluate cardiac or aortic trauma:
- Echocardiogram (TTE, TEE)
- MRI Cardiac (CPT® 75557, CPT® 75561, and CPT® 75565)
- CT Cardiac (CPT® 75572)
- CCTA (CPT® 75574)
- CTA Chest (CPT® 71275)

**References**

CD-11: Section left intentionally blank
## CD-12.1: Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)

<table>
<thead>
<tr>
<th>CD-12: Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD-12.1: Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)</td>
</tr>
</tbody>
</table>
CD-12.1: Oncologic Indications for Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD)

- MUGA evaluation of LV ejection fraction and wall motion analysis are appropriate - if an echocardiogram is not appropriate and ANY of the following chemotherapy-related indications:
  - Determine LV function in individuals on cardiotoxic chemotherapeutic drugs.
    - The time frame should be determined by the provider, but no more often than baseline and at every 6 weeks.
    - May repeat every 4 weeks if cardiotoxic chemotherapeutic drug is withheld for significant left ventricular cardiac dysfunction
  - If the LVEF is <50% on echocardiogram than follow up can be done with MUGA at appropriate intervals.

- Echocardiography vs. MUGA for Determining Left Ventricular Ejection Fraction (LVEF) in Individuals on Cardiotoxic Chemotherapy Drugs:
  - eviCore guidelines support using echocardiography rather than MUGA for the determination of LVEF and/or wall motion EXCEPT in one of the circumstances described previously in CD-3.4: MUGA Study – Cardiac Indications.

Background and Supporting Information

- Advantages of Echocardiography in comparison to MUGA in individuals on cardiotoxic chemotherapy:
  - No ionizing radiation
  - No IV access required when echo contrast is not used
  - Allows view of the pericardium to look for effusion
  - Allows estimate of pulmonary pressure
  - May allow visualization of a clot or tumor in the Inferior Vena Cava (IVC) and/or the right heart

References